SIRT6 signaling as an underexplored mechanistic node in nanoformulation‐based neuroinflammation therapy for Alzheimer's disease

Chronic microglial neuroinflammation is a core driver of Alzheimer's disease (AD). Wei et al. recently reported a blood‐brain barrier (BBB)‐penetrating, microglia‐targeting nanomodulator (Res@TcMNP/ASO) that simultaneously suppressed NF‐κB signaling and enhanced NRF2‐dependent antioxidant defense in chronically activated microglia, yet the molecular node coupling these two opposing circuits was not identified. In this perspective, drawing on primary literature spanning microglial inflammation, neuronal genome maintenance, tau regulation, and oncology, I propose that sirtuin 6 (SIRT6) is a plausible upstream candidate for this coordinated effect. SIRT6, a NAD ⁺ ‐dependent chromatin deacetylase, restrains NF‐κB through H3K9 deacetylation at RELA target promoters and, in parallel, deacetylates and stabilizes NRF2 to amplify antioxidant transcription; its decline in the aging and AD brain promotes DNA damage and GSK3‐driven tau hyperphosphorylation. Because a microglia‐restricted carrier confines pathway modulation to the relevant cell population, this delivery strategy is well matched to a SIRT6‐centered mechanism, while the context‐dependent, potentially oncogenic nature of systemic SIRT6 activation reinforces the rationale for such restricted delivery. I outline specific loss‐ and gain‐of‐function experiments to test whether microglial SIRT6 mediates the dual‐pathway effects of Res@TcMNP/ASO, offering a falsifiable hypothesis to guide future mechanistic and therapeutic work.